Insulin Lispro
From PeptidePlaza, the free peptide reference · Entry #1065 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Insulin Lispro (also known as 28(B)-Lys-29(B)-Pro-Insulin, Lyumjev, insuline lispro, Insulina lispro) is a metabolic research peptide. Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.
Insulin Lispro is an FDA-approved insulin receptor agonist indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is a rapid-acting human insulin analog that works by mimicking the action of natural insulin to regulate blood glucose levels. Approved in 1996, it is administered via intravenous or subcutaneous routes. Research on Insulin Lispro has focused on its role in managing type 1 and type 2 diabetes, as well as hyperglycemia. The literature includes reviews on its clinical use and comparisons with other insulin analogues.
1 Mechanism of action
Insulin receptor agonist (agonist)
Primary targets: Insulin receptor
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Diabetes Mellitus
- Hyperglycemia
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
2.2 Side effects
- Hypoglycemia
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
3 Chemical and physical properties
| CAS number | 133107-64-9 |
|---|---|
| Molar mass | 5814 g/mol |
| Purity (typical) | Not independently verified |
| Brand names | ADMELOG |
| Route | INTRAVENOUS, SUBCUTANEOUS |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Insulin receptor |
4 Research studies (8)
- [Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity]
Revue medicale de Liege (2024) · Review - Insulin lispro
The New England journal of medicine (1997) · Review - Insulin lispro update
The Diabetes educator (2002) - Insulin Lispro
(2026) - Insulin analogues
Current medical research and opinion (2002) · Review - Gestational diabetes mellitus
Saudi medical journal (2015) · Review - Insulin and Lispro Insulin: What is Common and Different in their Behavior?
Current protein & peptide science (2017) · Review - [Insulin lispro]
Nihon rinsho. Japanese journal of clinical medicine (2001) · Review
5 Safety and risk profile
5.1 Regulatory status
Insulin Lispro is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
5.2 Contraindications
Conditions and populations in which use is contraindicated:
- During episodes of hypoglycemia
- Hypersensitivity to insulin lispro or any excipients in ADMELOG
5.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics | Increased risk of hypoglycemia | High |
| Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones | Decreased blood glucose lowering effect | High |
| Alcohol, beta-blockers, clonidine, lithium salts, pentamidine | May increase or decrease blood glucose lowering effect | High |
| Beta-blockers, clonidine, guanethidine, reserpine | May blunt signs and symptoms of hypoglycemia | High |
5.4 Long-term risks
- transmission of blood-borne pathogens
- hyperglycemia or hypoglycemia with changes in insulin regimen
- hypoglycemia
- hypersensitivity reactions
- hypokalemia
- fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs)
- hyperglycemia and ketoacidosis due to insulin pump device malfunction
5.5 Research best practices
- dispense in the original sealed carton with the enclosed Instructions for Use
- do not freeze and do not use ADMELOG if it has been frozen
- protect from direct heat and light
- in-use (opened) ADMELOG vials and ADMELOG SoloStar pens must be used within 28 days or be discarded
6 Frequently asked questions
- What is Insulin Lispro used for?
- Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is used to manage blood sugar levels in individuals with both type 1 and type 2 diabetes, as well as hyperglycemia.
- How does Insulin Lispro work?
- Insulin Lispro functions as an insulin receptor agonist. It is a rapid-acting human insulin analog that mimics the action of natural insulin, binding to insulin receptors to facilitate glucose uptake by cells and lower blood glucose levels.
- Is Insulin Lispro FDA approved?
- Yes, Insulin Lispro is FDA approved. It received its first approval in 1996 and is marketed under names such as ADMELOG and Lyumjev for the treatment of diabetes mellitus.
- What are the side effects of Insulin Lispro?
- Common side effects associated with Insulin Lispro include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash. Hypoglycemia can be life-threatening, and patients should monitor blood glucose levels closely.
- What are the contraindications for Insulin Lispro?
- Insulin Lispro is contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to insulin lispro or any of the excipients in the ADMELOG formulation.
7 References
- Insulin Lispro — compound summary PubChem. View source
- Insulin Lispro — molecule record ChEMBL. View source
- Insulin Lispro — FDA approved prescribing information U.S. Food and Drug Administration. View source
- Insulin Lispro — published literature (885 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Insulin Lispro.
Also targets Insulin receptor
Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.
Also targets Insulin receptor
Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.
Also targets Insulin receptor
Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.
Also targets Insulin receptor
Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.
Also targets Insulin receptor
Insulin Zinc, Extended is an insulin receptor agonist currently in Phase 2 clinical trials.